JP2007509926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509926A5 JP2007509926A5 JP2006537909A JP2006537909A JP2007509926A5 JP 2007509926 A5 JP2007509926 A5 JP 2007509926A5 JP 2006537909 A JP2006537909 A JP 2006537909A JP 2006537909 A JP2006537909 A JP 2006537909A JP 2007509926 A5 JP2007509926 A5 JP 2007509926A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- deoxynojirimycin
- pharmaceutical composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical class OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002305 glucosylceramides Chemical class 0.000 claims 2
- 150000002339 glycosphingolipids Chemical class 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- -1 polycyclic alcohols Chemical class 0.000 claims 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims 1
- MDVGOOIANLZFCP-UHFFFAOYSA-N 1-adamantylmethanol Chemical compound C1C(C2)CC3CC2CC1(CO)C3 MDVGOOIANLZFCP-UHFFFAOYSA-N 0.000 claims 1
- DZKIUEHLEXLYKM-UHFFFAOYSA-N 9-phenanthrol Chemical compound C1=CC=C2C(O)=CC3=CC=CC=C3C2=C1 DZKIUEHLEXLYKM-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 102000004366 Glucosidases Human genes 0.000 claims 1
- 108010056771 Glucosidases Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 239000000232 Lipid Bilayer Substances 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- VLLNJDMHDJRNFK-UHFFFAOYSA-N adamantan-1-ol Chemical compound C1C(C2)CC3CC2CC1(O)C3 VLLNJDMHDJRNFK-UHFFFAOYSA-N 0.000 claims 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000024386 fungal infectious disease Diseases 0.000 claims 1
- 208000000069 hyperpigmentation Diseases 0.000 claims 1
- 230000003810 hyperpigmentation Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229920001281 polyalkylene Polymers 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078395A EP1528056A1 (en) | 2003-10-29 | 2003-10-29 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| EP03078395.5 | 2003-10-29 | ||
| PCT/NL2004/000761 WO2005040118A1 (en) | 2003-10-29 | 2004-10-29 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012091984A Division JP5730808B2 (ja) | 2003-10-29 | 2012-04-13 | デオキシノジリマイシン類似体、及びグルコシルセラミダーゼ阻害剤としてのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509926A JP2007509926A (ja) | 2007-04-19 |
| JP2007509926A5 true JP2007509926A5 (enExample) | 2007-12-13 |
| JP5016925B2 JP5016925B2 (ja) | 2012-09-05 |
Family
ID=34400526
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006537909A Expired - Lifetime JP5016925B2 (ja) | 2003-10-29 | 2004-10-29 | デオキシノジリマイシン類似体、及びグルコシルセラミダーゼ阻害剤としてのその使用 |
| JP2012091984A Expired - Lifetime JP5730808B2 (ja) | 2003-10-29 | 2012-04-13 | デオキシノジリマイシン類似体、及びグルコシルセラミダーゼ阻害剤としてのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012091984A Expired - Lifetime JP5730808B2 (ja) | 2003-10-29 | 2012-04-13 | デオキシノジリマイシン類似体、及びグルコシルセラミダーゼ阻害剤としてのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7528153B2 (enExample) |
| EP (2) | EP1528056A1 (enExample) |
| JP (2) | JP5016925B2 (enExample) |
| AU (1) | AU2004284012B2 (enExample) |
| CA (1) | CA2551060C (enExample) |
| CY (1) | CY1118191T1 (enExample) |
| DK (1) | DK1680403T3 (enExample) |
| ES (1) | ES2594356T3 (enExample) |
| HU (1) | HUE029637T2 (enExample) |
| IL (1) | IL175260A0 (enExample) |
| PL (1) | PL1680403T3 (enExample) |
| PT (1) | PT1680403T (enExample) |
| SI (1) | SI1680403T1 (enExample) |
| WO (1) | WO2005040118A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1680112E (pt) * | 2003-10-29 | 2011-03-24 | Genzyme Corp | N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina ou um seu sal aceite na indústria farmacêutica para ser usado no tratamento da resistência à insulina |
| EP1528056A1 (en) | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| WO2005092334A2 (en) * | 2004-03-25 | 2005-10-06 | David Priestman | Use of n-substituted imino sugars for appetite suppression |
| WO2006053043A2 (en) | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
| FR2887549B1 (fr) * | 2005-06-23 | 2009-07-10 | Centre Nat Rech Scient | Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation |
| FR2894482A1 (fr) * | 2005-12-14 | 2007-06-15 | Galderma Sa | Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema |
| DE602007008870D1 (de) * | 2006-04-24 | 2010-10-14 | Amc Amsterdam | Verbessertes verfahren zur behandlung von cystischer fibrose |
| HUE026057T2 (en) | 2006-05-09 | 2016-05-30 | Genzyme Corp | Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis |
| GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| EP2167485B1 (en) | 2007-05-31 | 2015-09-30 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| EP2209473B1 (en) | 2007-10-05 | 2017-11-22 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
| US8497122B2 (en) | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| RU2578947C2 (ru) | 2008-10-03 | 2016-03-27 | Джензайм Корпорейшн | Ингибиторы глюкозилцерамидсинтазы 2-ациламинопропанольного типа |
| ES2919563T3 (es) * | 2009-02-20 | 2022-07-27 | Enhanx Biopharm Inc | Sistema de administración de medicamentos a base de glutatión |
| EP2411526A4 (en) * | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | MODULATORS OF GANGLIOSID BIOSYNTHESIS |
| CN102740852A (zh) * | 2009-12-07 | 2012-10-17 | 牛津大学之校长及学者 | 用于抑制破骨细胞形成和/或破骨细胞活化的n-取代的脱氧野尻霉素化合物 |
| US9301962B2 (en) | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| DK2571503T3 (en) | 2010-05-14 | 2015-04-20 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS |
| ES2371398B1 (es) * | 2010-06-04 | 2013-05-20 | Bioglane, S.L.N.E. | Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales. |
| EP2533051A1 (en) | 2011-06-06 | 2012-12-12 | Centogene GmbH | Method for the diagnosis of Gaucher's disease |
| WO2014028734A1 (en) * | 2012-08-15 | 2014-02-20 | The Procter & Gamble Company | Human ex vivo skin model and use in methods of identifying modulators of skin inflammation |
| WO2014143999A1 (en) | 2013-03-15 | 2014-09-18 | Unither Virology, Llc | Antibacterial compounds |
| JP2016525676A (ja) * | 2013-05-02 | 2016-08-25 | ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード | リピドミックバイオマーカー |
| EP2991488A4 (en) * | 2013-05-02 | 2016-12-21 | The Chancellor Masters And Scholars Of The Univ Of Oxford | GLYCOLIPID INHIBITION BY IMINO SUGAR |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| CN106029653A (zh) | 2014-01-31 | 2016-10-12 | 达纳-法伯癌症研究所股份有限公司 | 二氨基嘧啶苯砜衍生物及其用途 |
| MX377534B (es) | 2014-02-28 | 2025-03-10 | Tensha Therapeutics Inc | Compuestos para usarse en el tratamiento de hiperinsulinemia. |
| EP3122726B1 (en) | 2014-03-27 | 2018-08-29 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| MX2017001757A (es) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Derivados de dihidropteridinona y sus usos. |
| MX2017001756A (es) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Derivados de diazepano y sus usos. |
| EA033325B1 (ru) | 2014-10-27 | 2019-09-30 | Тэнша Терапеутикс, Инк. | Ингибиторы бромодомена |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| HK1256417A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩並三唑並二氮雜環庚三烯及其用途 |
| CR20180199A (es) | 2015-09-11 | 2018-05-25 | Dana Farber Cancer Inst Inc | Acetamida tienotriazolodiazepinas y usos de las mismas |
| RU2742035C2 (ru) | 2015-11-25 | 2021-02-01 | Дана-Фарбер Кэнсер Инститьют, Инк. | Бивалентные ингибиторы бромодоменов и пути их применения |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| US20220257604A1 (en) * | 2019-03-08 | 2022-08-18 | University Of Virginia Patent Foundation | Compositions and methods for modulating viral infections by regulating glucosylceramides |
| CA3182334A1 (en) * | 2020-05-07 | 2021-11-11 | Alectos Therapeutics Inc. | Non-lysosomal glucosylceramidase inhibitors and uses thereof |
| WO2022227287A1 (zh) * | 2021-04-25 | 2022-11-03 | 中南大学 | Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用 |
| CN118459393B (zh) * | 2024-04-29 | 2025-11-28 | 中国科学院成都生物研究所 | 一类具有α-葡萄糖苷酶抑制活性的D-木糖衍生物及制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2504000B2 (ja) | 1986-09-02 | 1996-06-05 | 日本新薬株式会社 | グルコシルモラノリン誘導体 |
| US6177447B1 (en) | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| BR9902585A (pt) | 1999-02-11 | 2000-09-26 | Claudio Cerqueira Lopes | Um novo processo de sìntese de aza-açúcares com atividade biológica |
| GB0100889D0 (en) * | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
| US6235737B1 (en) | 2000-01-25 | 2001-05-22 | Peter Styczynski | Reduction of hair growth |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| AU2003246942B2 (en) * | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| JP4585851B2 (ja) * | 2002-07-17 | 2010-11-24 | アクテリオン ファーマシューティカルズ リミテッド | グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体 |
| GB0229476D0 (en) | 2002-12-17 | 2003-01-22 | Oxford Glycosciences Uk Ltd | Novel process |
| PT1680112E (pt) | 2003-10-29 | 2011-03-24 | Genzyme Corp | N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina ou um seu sal aceite na indústria farmacêutica para ser usado no tratamento da resistência à insulina |
| EP1528056A1 (en) * | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| WO2005063706A1 (en) | 2003-12-23 | 2005-07-14 | Macrozyme Dnm B.V. | Synthesis of nojirimycins |
| EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
-
2003
- 2003-10-29 EP EP03078395A patent/EP1528056A1/en not_active Withdrawn
-
2004
- 2004-10-29 CA CA2551060A patent/CA2551060C/en not_active Expired - Lifetime
- 2004-10-29 SI SI200432349A patent/SI1680403T1/sl unknown
- 2004-10-29 AU AU2004284012A patent/AU2004284012B2/en not_active Expired
- 2004-10-29 JP JP2006537909A patent/JP5016925B2/ja not_active Expired - Lifetime
- 2004-10-29 PL PL04793685T patent/PL1680403T3/pl unknown
- 2004-10-29 ES ES04793685.1T patent/ES2594356T3/es not_active Expired - Lifetime
- 2004-10-29 PT PT47936851T patent/PT1680403T/pt unknown
- 2004-10-29 DK DK04793685.1T patent/DK1680403T3/en active
- 2004-10-29 US US10/595,589 patent/US7528153B2/en not_active Expired - Lifetime
- 2004-10-29 WO PCT/NL2004/000761 patent/WO2005040118A1/en not_active Ceased
- 2004-10-29 EP EP04793685.1A patent/EP1680403B1/en not_active Expired - Lifetime
- 2004-10-29 HU HUE04793685A patent/HUE029637T2/en unknown
-
2006
- 2006-04-27 IL IL175260A patent/IL175260A0/en active IP Right Grant
-
2012
- 2012-04-13 JP JP2012091984A patent/JP5730808B2/ja not_active Expired - Lifetime
-
2016
- 2016-09-28 CY CY20161100964T patent/CY1118191T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509926A5 (enExample) | ||
| CA2551060A1 (en) | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | |
| Twomey et al. | Successful treatment of adrenal metastases from large-cell carcinoma of the lung | |
| JP2010503688A5 (enExample) | ||
| US9907777B2 (en) | Methods for treating bipolar disorder | |
| JP2004533444A5 (enExample) | ||
| JP2005519083A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2012502037A5 (enExample) | ||
| JP2005502635A5 (enExample) | ||
| KR880011088A (ko) | 페닐 카르바메이트 | |
| RU2008133161A (ru) | Ингибиторы тирозин киназ и их применение | |
| JP2003528799A5 (enExample) | ||
| AU2002318302A1 (en) | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate | |
| JP2007502832A5 (enExample) | ||
| Lansford Jr et al. | Synthesis Anti-diarrhoeal Agents--I. Some Pharmacological Properties of R 1132 and Related Compounds | |
| CA2446890A1 (en) | Deuterated 3-piperidinopropiophenones and pharmaceutical drugs containing these compounds | |
| CA3062452A1 (en) | Compositions, combinations, and methods thereof for treatment of neurological disorders | |
| CN104306363B (zh) | 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用 | |
| JP2004531478A5 (enExample) | ||
| JP2006510658A5 (enExample) | ||
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| EP1857442A3 (en) | Novel antimycobacterial compounds | |
| CA2476825A1 (en) | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases | |
| JP2006510659A5 (enExample) |